

wherein

X₁ is Aib;

X₂ is Aib;

K at position 20 is chemically modified through conjugation to the
epsilon-amino group of the K side-chain with ([2-(2-Amino-
ethoxy)-ethoxy]-acetyl)₂-(γGlu)_a-CO-(CH₂)_b-CO₂H wherein a is 1
to 2 and b is 10 to 20;

X₃ is Phe or 1-Nal;

and the C-terminal amino acid is optionally amidated as a C-
terminal primary amide (SEQ ID NO: 11),

or a pharmaceutically acceptable salt thereof.

In another aspect of the present disclosure, there is provided a pharmaceutical
composition comprising a compound disclosed herein with a pharmaceutically acceptable
carrier, diluent, or excipient.

In a further aspect of the present disclosure, there is provided a compound
disclosed herein for use in therapy.

In another aspect of the present disclosure, there is provided a compound
disclosed herein for use in the treatment of type 2 diabetes mellitus.

In a further aspect of the present disclosure, there is provided a compound
disclosed herein, wherein an effective amount of one or more agents selected from
metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors, and
sodium glucose co-transporters is to be simultaneously, separately or sequentially
combined with said compound.

In another aspect of the present disclosure, there is provided a use of a compound
disclosed herein in the manufacture of a medicament for treating type 2 diabetes mellitus,
wherein the medicament is to be administered to a patient in need thereof.

Description

An embodiment of the present invention provides a compound of Formula I:

YX₁EGTFTSDYSIX₂LDKIAQKAX₃VQWLIAGGPSSGAPPPS;

and the C-terminal amino acid is amidated as a C-terminal primary amide (SEQ ID NO: 3),

or a pharmaceutically acceptable salt thereof.

11. The compound of Claim 1, wherein

X₁ is Aib

X₂ is Aib;

K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)₂-(γGlu)₂-CO-(CH₂)₁₈-CO₂H;


X₃ is 1-Nal;

and the C-terminal amino acid is amidated as a C-terminal primary amide (SEQ ID NO: 4),

or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising the compound of Claim 10 with a pharmaceutically acceptable carrier, diluent, or excipient.
13. The compound of claim 11 for use in therapy.
14. The compounds of claim 11 for use in the treatment of type 2 diabetes mellitus.
15. The compound of claim 11, wherein an effective amount of one or more agents selected from metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors, and sodium glucose co-transporters is to be simultaneously, separately, or sequentially combined with said compound.

16. The compound of Claim 1, wherein the Formula is:



17. A pharmaceutical composition comprising the compound of Claim 16 with a pharmaceutically acceptable carrier, diluent, or excipient.
18. Use of a compound of any one of claims 1-11 or 16 in the manufacture of a medicament for treating type 2 diabetes mellitus, wherein the medicament is to be administered to a patient in need thereof.
19. The use of Claim 18, wherein an effective amount of one or more agents selected from metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors, and sodium glucose co-transporters is to be further administered simultaneously, separately, or sequentially in combination with the medicament.
20. The compound of Claim 16, for use in therapy.
21. The compound of Claim 16, for use in the treatment of type 2 diabetes mellitus.
22. The compound of Claim 16, wherein one or more agents selected from metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase 4 inhibitors, and sodium glucose co-transporters is to be simultaneously, separately, or sequentially combined with said compound.